Nara, Japan
Nara, Japan

Sharp Corporation is a Japanese multinational corporation that designs and manufactures electronic products. Headquartered in Abeno-ku, Osaka, Japan, Sharp employed 50,253 people worldwide as of March 2014. The company was founded in September 1912 and takes its name from one of its founder's first inventions, the Ever-Sharp mechanical pencil, which was invented by Tokuji Hayakawa in 1915. Sharp Corporation was previously the fifth-largest television manufacturer in the world, after Samsung, LG, Sony, and Panasonic. Since 2000, Sharp has heavily invested in LCD panel manufacturing plants; Kameyama in 2004, Sakai in 2009. The Sakai plant is still the only 10th generation LCD manufacturing plant on the globe and best fit for production of 60 inch or larger panels. However, the 2008 financial crisis and strong Yen significantly lowered world demand for Japanese LCD panels. Furthermore, the switch to digital TV broadcasting was virtually completed in Japan by the middle of 2011. Via Japanese government issued coupons for digital TV sets, consumers were encouraged to purchase digital TV sets until March 2011. This hit the Japanese LCD TV market, reducing it almost by half from 2010. All of those events strongly hit Sharp's LCD business. As the result, the Sakai LCD plant suffered a reduced operating rate until Fall 2012. 2012 was the 100th anniversary for Sharp but it announced the worst financial record in its history, with a loss of 376 billion yen in April 2012. In September, Sharp announced job cuts. In 2014, Sharp was able to stem losses and deliver a positive net income for its first quarter results. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Sharp Corporation | Date: 2017-01-30

A novel process is provided for the efficient preparation of an asymmetric compound of structural formula I: comprising a copper-catalyzed, carbon-nitrogen cross-coupling step. The process described as part of the present invention can be used to manufacture poly (ADP-ribose) polymerase (PARP) inhibitors, which may be useful for the treatment of cancer. In particular, the present invention describes a process for the manufacture of the PARP inhibitor, 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide.


Patent
Sharp Corporation | Date: 2017-04-05

The present invention relates generally to the use of gene mutations, whose presence or absence are useful for predicting a patients response to treatment with an anti-proliferative agent, in particular a WEE1 inhibitor. The presence or absence of a mutation to the TP53 gene, can be used to predict response to treatment with a WEE1 inhibitor in a patient presenting with a cancerous condition.


Patent
Sharp Corporation | Date: 2017-01-25

Described herein are polymeric nanoparticles that comprise 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[l,2,4]-triazolo-[3,4-fJ[1,6]- naphthyridin-3-one (Compound A), or a pharmaceutically acceptable salt thereof, and methods of making and using such nanoparticles.The nanoparticle comprises about 50 to about 99.8 weight percent of a diblock poly(lactic) acid-poly(ethylene)glycol copolymer or a diblock poly(lactic acid-co-glycolic acid)-poly(ethylene)glycol copolymer, wherein the total amount of poly(ethylene)glycol in the nanoparticle is about 10 to about 30 weight percent poly(ethylene)glycol and about 0.2 to about 30 weight percent of Compound A.


Patent
Sharp Corporation and MSD R & D China Co. | Date: 2017-01-18

The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.


Patent
Sharp Corporation | Date: 2017-02-08

Compounds of Formula I are described: wherein R1 and R2 are defined herein. The compounds of Formula I are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV, and the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.


Patent
Sharp Corporation | Date: 2017-05-10

Pharmaceutical compositions suitable for oral administration in solid dosage forms are described. The compositions comprise an effective amount of a drug compound in the form of a salt, wherein the drug salt is characterized by conversion to a less soluble form of the drug compound under certain pH conditions, and an anti-nucleating agent.


The present invention relates to processes for preparing compounds of Formula I. Such compounds include intermediates in the manufacture of 7-oxo-1,6- diazabicyclo[3.2.1 ]octane-2-carboxamide beta-lactamase inhibitors such as (2S,5R)-7-oxo-N- 5 piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide. The present invention also relates to novel intermediates formed i these processes. The present invention relates to a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof.


Patent
Sharp Corporation | Date: 2017-09-27

Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.


Patent
Sharp Corporation | Date: 2017-09-27

A process for refolding recombinant chymotrypsin produced from prokaryote host cells is described. In particular, the present invention provides a process for refolding recombinant chymotrypsin produced from E. coli is described.


Patent
Sharp Corporation | Date: 2017-09-27

The present invention relates to methods for the recombinant expression of chlamydia major outer membrane protein (MOMP) comprising transforming a population of E. coli host cells with an expression vector comprising a nucleic acid molecule that encodes chlamydia MOMP and encodes a leader sequence for targeting the MOMP to the outer membrane of the cell, wherein the nucleic acid molecule is operatively linked to a promoter. The method of the invention allows expression of MOMP in the outer membrane of the cell, which leads to protein folding that is more like native MOMP relative to a MOMP protein that is expressed intracellularly. Also provided by the invention are uses of the recombinant MOMP in pharmaceutical compositions and methods for the treatment and/or prophylaxis of chlamydia infection and/or the effects thereof.

Loading Sharp Corporation collaborators
Loading Sharp Corporation collaborators